Ellevest Inc. lifted its position in Agilent Technologies, Inc. (NYSE:A) by 5.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,434 shares of the medical research company’s stock after buying an additional 135 shares during the quarter. Ellevest Inc.’s holdings in Agilent Technologies were worth $309,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Norges Bank acquired a new stake in Agilent Technologies in the 4th quarter worth approximately $358,609,000. Winslow Capital Management LLC lifted its holdings in shares of Agilent Technologies by 1,260.9% during the fourth quarter. Winslow Capital Management LLC now owns 1,963,381 shares of the medical research company’s stock worth $232,642,000 after buying an additional 1,819,111 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Agilent Technologies by 161.7% during the fourth quarter. Principal Financial Group Inc. now owns 1,140,216 shares of the medical research company’s stock worth $135,104,000 after buying an additional 704,459 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Agilent Technologies by 190.1% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 993,065 shares of the medical research company’s stock worth $117,670,000 after buying an additional 650,712 shares during the last quarter. Finally, Clarus Group Inc. acquired a new position in shares of Agilent Technologies during the first quarter worth approximately $3,398,000.
A number of brokerages have recently commented on A. Citigroup upgraded Agilent Technologies from a “neutral” rating to a “buy” rating and set a $150.00 price target for the company in a report on Thursday, March 18th. SVB Leerink upped their price target on Agilent Technologies from $130.00 to $140.00 and gave the stock an “outperform” rating in a report on Wednesday, February 17th. Robert W. Baird upped their target price on Agilent Technologies from $133.00 to $137.00 and gave the company an “outperform” rating in a research note on Wednesday, February 17th. Redburn Partners upgraded Agilent Technologies from a “neutral” rating to a “buy” rating in a research note on Friday, March 19th. Finally, Canaccord Genuity upped their target price on Agilent Technologies from $80.00 to $85.00 and gave the company a “hold” rating in a research note on Monday, May 3rd. Seven equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $108.03.
Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Monday, February 15th. The medical research company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.17. The business had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.43 billion. Agilent Technologies had a return on equity of 21.02% and a net margin of 13.47%. During the same quarter last year, the business earned $0.81 earnings per share. As a group, sell-side analysts expect that Agilent Technologies, Inc. will post 3.67 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Wednesday, April 28th. Investors of record on Tuesday, April 6th were issued a $0.194 dividend. This represents a $0.78 annualized dividend and a yield of 0.59%. The ex-dividend date was Monday, April 5th. Agilent Technologies’s dividend payout ratio is 23.78%.
Agilent Technologies announced that its board has approved a share buyback program on Tuesday, February 16th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire up to 5% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.
In other Agilent Technologies news, SVP Michael Tang sold 500 shares of the stock in a transaction dated Friday, April 23rd. The stock was sold at an average price of $137.00, for a total value of $68,500.00. Following the transaction, the senior vice president now owns 53,030 shares of the company’s stock, valued at $7,265,110. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael R. Mcmullen sold 15,095 shares of the stock in a transaction dated Thursday, April 8th. The shares were sold at an average price of $130.26, for a total value of $1,966,274.70. Following the completion of the transaction, the chief executive officer now directly owns 279,124 shares in the company, valued at approximately $36,358,692.24. The disclosure for this sale can be found here. Insiders sold 34,614 shares of company stock worth $4,572,425 in the last three months.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Featured Article: Why is insider trading harmful?
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.